Company profile: Bamboo Therapeutics
1.1 - Company Overview
Company description
- Provider of gene therapy development, research, and manufacturing for rare genetic diseases, advancing the work of Dr. Richard Jude Samulski at UNC’s Gene Therapy Center from the laboratory into human clinical trials to meet drug approval requirements. Operates a Sanford, North Carolina manufacturing complex using specialized methodologies and advanced techniques.
Products and services
- Gene Therapy Manufacturing: Clinical-trial-grade operations at a Sanford, North Carolina complex that produces gene therapies using advanced techniques and integrates the acquired UNC-Chapel Hill Vector Core manufacturing facility
- Gene Therapy Development: Custom-engineered programs that develop therapies for rare genetic diseases, progressing Dr. Richard Jude Samulski’s laboratory work into human clinical trials to meet drug approval requirements
- Gene Therapy Research: Research-grade investigations focused on developing gene therapies for rare genetic diseases, extending laboratory work at UNC’s Gene Therapy Center led by Dr. Richard Jude Samulski
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bamboo Therapeutics
Sangamo Therapeutics
HQ: United States
Website
- Description: Provider of engineered DNA-binding protein-based therapeutics, conducting clinical trials of gene and cell therapy candidates including: giroctocogene fitelparvovec for hemophilia A; ST-920 for Fabry disease; TX200 for patients undergoing a kidney transplant; SB-525/giroctocogene fitelparvovec (Phase 1/2); and BIVV003 ex vivo cell therapy for severe sickle cell disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sangamo Therapeutics company profile →
Precision Biomonitoring
HQ: Canada
Website
- Description: Provider of biotechnology and research specializing in various types of DNA and testing services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision Biomonitoring company profile →
Eagle Genomics
HQ: United Kingdom
Website
- Description: Provider of enterprise software enabling management, orchestration and exploitation of genomics and other life sciences data. Solutions include e[datascientist] for multi-omics data and metadata; Network Life Sciences Platform leveraging network science, AI and hypergraphs; Valuation and Decision Engine for prioritizing entity relationships; cloud-based Analysis Hub; Catalog with governance; and a Multi-layer Hypergraph tool.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eagle Genomics company profile →
Vector BioMed
HQ: United States
Website
- Description: Provider of state-of-the-art custom vector design and GMP manufacturing, specializing in Lentiviral vector production for research, pre-clinical, IND-enabling, and clinical trials using a serum-free, chemically-defined process; algorithm-based vector design optimized for titer, transduction, and transgene expression; custom assay development; and support services for clinical development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vector BioMed company profile →
BridgeBio Pharma
HQ: United States
Website
- Description: Provider of precision medicines for genetic diseases and cancers, developing assets including BBP-398 (SHP2 inhibitor for MAPK/RAS-driven cancers), BBP-631 (AAV5 gene therapy for congenital adrenal hyperplasia), BBP-818 (AAV gene therapy for classic galactosemia), BBP-589 (recombinant collagen 7 for dystrophic epidermolysis bullosa), BBP-681 (topical PI3KA inhibitor), and BBP-711 (GO inhibitor).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BridgeBio Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bamboo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bamboo Therapeutics
2.2 - Growth funds investing in similar companies to Bamboo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bamboo Therapeutics
4.2 - Public trading comparable groups for Bamboo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →